Price
No data yet.
Social Signal Score
Analyst Ratings
33 analystsRevenue
$658.70M+749.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Morrissey
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,077
- Beta
- 0.42
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 17.98
Financials
Revenue
$658.70M+749.0%Net Income
$218.09M+520.9%EBITDA
$289.72M+637.7%Free Cash Flow
$277.47M+233.8%EPS (diluted)
$0.85+608.3%Shares Outstanding (diluted)
255.75M-15.1%Operating Expenses
$364.04MCash & Debt
$892.02MReturn of Capital
$249.96MRevenue by Segment (annual)
$4.64BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.32B | $782.57M | $2.88 |
| 2024 | $2.17B | $521.27M | $1.80 |
| 2023 | $1.83B | $207.76M | $0.65 |
| 2022 | $1.61B | $182.28M | $0.57 |
| 2021 | $1.43B | $231.06M | $0.73 |
| 2020 | $987.54M | $111.78M | $0.36 |
| 2019 | $967.77M | $321.01M | $1.06 |
| 2018 | $853.83M | $690.07M | $2.32 |
| 2017 | $452.48M | $154.23M | $0.52 |
| 2016 | $191.45M | $-70.22M | $-0.28 |
| 2015 | $37.17M | $-169.74M | $-0.81 |
| 2014 | $25.11M | $-268.54M | $-1.38 |
| 2013 | $31.34M | $-244.76M | $-1.33 |
| 2012 | $47.45M | $-147.65M | $-0.92 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $4.23
- Implied price
- $63.51
- Return from $68.29
- -1.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $31.58 — -53.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -2.0% | -15.9% | -13.1% | -10.6% | -8.3% | -6.2% |
| 3.0% | -11.7% | -8.7% | -6.0% | -3.6% | -1.5% |
| 8.0% | -7.4% | -4.2% | -1.4% | 1.1% | 3.3% |
| 13.0% | -3.1% | 0.2% | 3.1% | 5.7% | 8.1% |
| 18.0% | 1.2% | 4.6% | 7.7% | 10.4% | 12.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (47)
- Newszacks.com·2d ago·Positive
Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsmarketbeat.com·4d ago·Neutral
Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABO Exelixis NASDAQ: EXEL is preparing for a transition from a company built around its CABO franchise to one with multiple products, as it advances seven pivotal studies of Zanza and weighs additional development opportunities, Chief Strategy Officer Andrew Peters said at the Jefferies London Healthcare Conference.
View source ↗ - Newsseekingalpha.com·4d ago·Positive
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript Exelixis, Inc. (EXEL) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newsfool.com·6d ago·Negative
Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything Cabometyx's sales keep growing, but generic competition looms by the end of the decade. Meanwhile, zanzalintinib could earn approval by March of 2027.
View source ↗ - News (RSS)fool·9d ago·Neutral
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch. These catalysts could impact growth down the road.
View source ↗ - Newsfool.com·9d ago·Neutral
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch. Exelixis' cabozantinib, addressing various types of cancer, has driven tremendous growth over the past 10 years. The company is now betting on a next-generation candidate that's approaching the finish line.
View source ↗ - News (RSS)seekingalpha·11d ago·Positive
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
View source ↗ - Newszacks.com·13d ago·Positive
Here's Why Exelixis (EXEL) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·20d ago·Neutral
Exelixis (EXEL) International Revenue in Focus: Trends and Expectations Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
View source ↗ - Newszacks.com·23d ago·Positive
EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales Exelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.
View source ↗ - News (RSS)investing·24d ago·Neutral
Exelixis Q3 2026 slides: CABOMETYX growth funds zanzalintinib push
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·24d ago·Neutral
What Exelixis (EXEL) Said on Its Q3 Earnings Call Exelixis NASDAQ: EXEL reported third-quarter 2026 revenue of approximately $659 million, supported by continued growth in its cabozantinib franchise and progress toward a potential launch of zanzalintinib in colorectal cancer.
View source ↗ - Newszacks.com·24d ago·Neutral
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·24d ago·Positive
Exelixis (EXEL) Surpasses Q3 Earnings and Revenue Estimates Exelixis (EXEL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.78 per share a year ago.
View source ↗ - Newsfool.com·29d ago·Negative
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy Regulators in the U.S. extended the review period for Exelixis' request to approve a new cancer drug. However, the company's most important medicine is performing well and still has several years of growth before facing generic competition.
View source ↗ - Newszacks.com·37d ago·Positive
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·38d ago·Neutral
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - News (RSS)investing·41d ago·Neutral
Exelixis Inc stock hits all-time high at 61.21 USD
View source ↗ - Newszacks.com·45d ago·Positive
Here's Why Exelixis (EXEL) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·53d ago·Positive
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·59d ago·Neutral
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
View source ↗ - Newszacks.com·60d ago·Positive
Here's Why Exelixis (EXEL) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsmarketbeat.com·66d ago·Neutral
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B Exelixis NASDAQ: EXEL President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential collaborations, while preparing for a planned launch of zanzalintinib in metastatic colorectal cancer.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·68d ago·Neutral
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle Exelixis NASDAQ: EXEL executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year.
View source ↗ - Newszacks.com·69d ago·Positive
Here's Why Exelixis (EXEL) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - News (RSS)seekingalpha·69d ago·Neutral
Exelixis: The FDA Delay Costs Less Than The Market Thinks
View source ↗ - Newsmarketbeat.com·69d ago·Negative
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises Exelixis NASDAQ: EXEL executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib through multiple late-stage studies.
View source ↗ - Newsseekingalpha.com·69d ago·Negative
Exelixis: The FDA Delay Costs Less Than The Market Thinks The FDA extended its review of Exelixis' zanzalintinib by three months, but no new clinical failure or safety signal was disclosed. At a 10% discount rate, three months reduces an asset's present value by only 2.35%, far less than Exelixis initially lost. CABOMETYX continues growing, and 2026 guidance includes no zanzalintinib launch revenue.
View source ↗ - News (RSS)yahoo·72d ago·Negative
Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay
View source ↗ - Newsbenzinga.com·72d ago·Negative
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In On Friday, the U.S. Food and Drug Administration (FDA) extended the review period for Exelixis Inc.‘s (NASDAQ:EXEL) new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for metastatic colorectal cancer by three months.
View source ↗ - News (RSS)investing·72d ago·Neutral
Exelixis stock falls as FDA extends zanzalintinib review
View source ↗ - Newsreuters.com·72d ago·Negative
U.S. FDA extends review of Exelixis' cancer drug The U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three months, the company said in a filing on Friday.
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - News (RSS)seekingalpha·75d ago·Positive
Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·75d ago·Positive
Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Exelixis, Inc. (EXEL) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newszacks.com·79d ago·Neutral
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue? Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)seekingalpha·82d ago·Negative
Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data
View source ↗ - Newsseekingalpha.com·82d ago·Negative
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data Exelixis is downgraded from "Strong Buy" to "Hold" due to lowered 2026 revenue guidance and mixed clinical trial outcomes. Zanzalintinib + TECENTRIQ achieved overall survival benefit in mCRC, but missed the non-liver metastases subgroup endpoint; FDA PDUFA date set for December 3, 2026. Q2 2026 revenues rose to $628.7M, but future sales growth is uncertain and full-year guidance was cut to $2.500–$2.550B.
View source ↗ - News (Marketaux)gurufocus.com·83d ago·Positive
EXEL Looks 18.3% Overvalued on GF Value™ After Patent Win On August 31, 2026, Exelixis <e[+313 characters]
View source ↗ - Newsbusinesswire.com·83d ago·Neutral
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District of Delaware in Exelixis' favor. The …
View source ↗ - Newsfxempire.com·86d ago·Positive
Strong Sales, Earnings Send Exelixis Shares Higher Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.
View source ↗ - Newszacks.com·94d ago·Positive
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsbusinesswire.com·98d ago·Negative
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law.
View source ↗
Earnings
Tue, Feb 9(in 3 months)
Consensus estimate $1.04 per share
Typical surprise +13.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$0.94 vs $0.89beat
- Wed, Aug 5$0.91 vs $0.85beat
- Tue, May 5$0.87 vs $0.77beat
- Tue, Feb 10$0.94 vs $0.77beat
- Tue, Nov 4$0.78 vs $0.69beat
- Mon, Jul 28$0.75 vs $0.65beat
Estimates and results for EXEL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EXEL officers and directors.
- Bought
- $1.2m
- Sold
- $41.2m
1 trade
30 trades
- Beckerle Mary Csold
- Wyszomierski Jack Lsold
- Eckhardt Sue Gailsold
- Aftab Danasold
- Haley Patrick J.sold
- Senner Christopher J.sold
- Hefti Brendasold
- Beckerle Mary Csold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (26d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (446d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (474d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (377d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (328d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
